Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC ...Middle East

HONG KONG, Nov. 3, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") announced the patient enrollment completion for the Phase III clinical trial of Ivonescimab (PD-1/VEGF bi-specific antibody, AK112) combined with chemotherapy for the treatment of EGFR-mutant locally advanced or...

Hence then, the article about akeso completes enrollment in phase iii trial of pd 1 vegf bispecific antibody ak112 combined with chemotherapy in egfr tki resistant nsq nsclc was published today ( Friday 04/11/2022 - 04:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC )

Also on site :

• Live-Action ‘Last Kids On Earth’ Gets Disney+ Pilot Order
• Memes, mariachis, and geopolitics! The explosive powder keg of Mexico vs. Ecuador
• Want to be an extra on the Chicago Bears-themed Hallmark holiday movie?